Inflammatory bowel disease
Conditions
Interventions
None listed
Sponsors
Nagoya University
Department of Endoscopy, TOYOTA Memorial Hospital, 1-1 Heiwa-cho, Toyota-shi, Aichi, Japan Department of Gastroenterology and Hepatology, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya, Japan Department of Gastroenterology, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Japan Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, 3-35 Michishita-cho Nakamura-ku Nagoya, Japan Department of Gastroenter
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [New onset group] Meet all of the following (1) to (3) (1) Cases newly diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) at Nagoya University Hospital or any research institute after January 1, 2013 (2) Age 18 or older at the time of new onset (3) Gender does not matter. [New treatment group] (1) Patients who started treatment with tacrolimus, infliximab, adalimumab, golimumab, tofacitinib, vedolizumab, cyclosporine, ustekinumab, cytapheresis, steroids, azathioprine, 5-ASA, local therapy, filgotinib, upadacitinib, mikilizumab, carotegrast methyl, risankizumab, zentacort, colletiment, osamonide, or guselkumab at Nagoya University Hospital or any research institute on or after January 1, 2013. (2) Patients must be 18 years of age or older at the time of starting new treatment. (3) Gender does not matter. [Postoperative follow-up group] Meet all of the following (1) to (3) (1) Patients who underwent surgical treatment for inflammatory bowel disease at Nagoya University Hospital or at each research institute during the study period from January 1, 2013 onwards (2) Patients must be aged 18 or older at the time of surgical treatment. (3) Gender does not matter. [Endoscopy group] Meet all of the following (1) to (3) (1) Patients who underwent endoscopic examination for inflammatory bowel disease at Nagoya University Hospital or at each research institute during the study period from January 1, 2013 onwards (2) Patients must be aged 18 or older at the time of endoscopic examination. (3) Gender does not matter.
Exclusion criteria
Exclusion criteria: [New onset group] -None [New treatment introduction group] -None [Postoperative follow-up observation group] -None [Endoscopy group] -None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy rates of newly introduced drugs in the short term (2 weeks and 2 months), mid-term (3 months and 6 months), and long term (1 year, 3 years, and 5 years), treatment continuation rates, and factors correlated with these | — |
Secondary
| Measure | Time frame |
|---|---|
| Rates of new treatment introduction, hospitalization, and surgery in newly diagnosed cases, and factors correlating with them Relapse and reoperation rates in postoperative cases, and factors correlating with them Efficacy rates, endoscopic improvement rates, and continuation rates of 1st-line, 2nd-line, and 3rd-line treatments, and factors correlating with them Endoscopic remission achievement rate, treatment continuation rate, hospitalization rate, and surgery rate for 2nd-line treatment in cases who achieved clinical remission with 1st-line treatment Efficacy of anti-TNF antibody preparations, IL12/23 (23) antibody preparations, and JAK inhibitors in cases with a history of anti-TNF antibody treatment, and efficacy after anti-TNF treatment and molecular targeted drug treatment Comparison with cases without treatment Efficacy of anti-TNF antibody preparations and IL12/23 (23) antibody preparations in cases with a history of IL12/23 (23) antibody preparation treatment, comparison with cases after anti-TNF treatment and without molecular targeted drug treatment Efficacy of anti-TNF antibody preparations and IL12/23 (23) antibody preparations in cases with a history of JAK treatment, comparison with cases without molecular targeted drug treatment Efficacy of anti-TNF antibody preparations, IL12/23 (23) antibody preparations, and JAK inhibitors in cases with a history of VDZ treatment, comparison with cases without molecular targeted drug treatment Endoscopic findings, scores, and clinical factors correlated with prognosis | — |
Countries
Japan
Contacts
Public ContactTsunaki Sawada
Nagoya University Hospitao Department of Endoscopy
Outcome results
None listed